UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 262

Sortiert nach

An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma

Nature communications, 2021-10, Vol.12 (1), p.5908-5908, Article 5908

2021

Volltextzugriff (PDF)

Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas

Journal of neuro-oncology, 2009-09, Vol.94 (3), p.299-312

2009

Volltextzugriff (PDF)

The Notch signaling pathway: a potential target for cancer immunotherapy

Journal of hematology and oncology, 2023-05, Vol.16 (1), p.45-45, Article 45

2023

Volltextzugriff (PDF)

Rat and Mouse Brain Tumor Models for Experimental Neuro-Oncology Research

Journal of neuropathology and experimental neurology, 2022-05, Vol.81 (5), p.312-329

2022

Volltextzugriff (PDF)

Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis

Clinical cancer research, 2016-11, Vol.22 (21), p.5337-5348

2016

Volltextzugriff (PDF)

Impact of tumor microenvironment on oncolytic viral therapy

Cytokine & growth factor reviews, 2010-04, Vol.21 (2), p.127-134

2010

Volltextzugriff (PDF)

Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth

Cancer cell, 2015-11, Vol.28 (5), p.569-581

2015

Volltextzugriff (PDF)

MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44

Scientific reports, 2021-04, Vol.11 (1), p.9219-11, Article 9219

2021

Volltextzugriff (PDF)

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

Scientific reports, 2015-07, Vol.5 (1), p.11483-11483, Article 11483

2015

Volltextzugriff (PDF)

Selective Endothelial Hyperactivation of Oncogenic KRAS Induces Brain Arteriovenous Malformations in Mice

Annals of neurology, 2021-05, Vol.89 (5), p.926-941

2021

Volltextzugriff (PDF)

Complex role of NK cells in regulation of oncolytic virus–bortezomib therapy

Proceedings of the National Academy of Sciences - PNAS, 2018-05, Vol.115 (19), p.4927-4932

2018

Volltextzugriff (PDF)

Histone modifiers at the crossroads of oncolytic and oncogenic viruses

Molecular therapy, 2022-06, Vol.30 (6), p.2153-2162

2022

Volltextzugriff (PDF)

A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases

Oncotarget, 2016-05, Vol.7 (19), p.27764-27777

2016

Volltextzugriff (PDF)

RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21

Molecular therapy, 2017-07, Vol.25 (7), p.1544-1555

2017

Volltextzugriff (PDF)

Pyruvate kinase M2 regulates homologous recombination-mediated DNA double-strand break repair

Cell research, 2018-10, Vol.28 (11), p.1090-1102

2018

Volltextzugriff (PDF)

Glioma and temozolomide induced alterations in gut microbiome

Scientific reports, 2020-12, Vol.10 (1), p.21002, Article 21002

2020

Volltextzugriff (PDF)

PRMT5 as a druggable target for glioblastoma therapy

Neuro-oncology (Charlottesville, Va.), 2018-05, Vol.20 (6), p.753-763

2018

Volltextzugriff (PDF)

Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells

PloS one, 2013-09, Vol.8 (9), p.e72882

2013

Volltextzugriff (PDF)

NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy

Clinical cancer research, 2022-04, Vol.28 (7), p.1460-1473

2022

Volltextzugriff (PDF)

Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors

Viruses, 2022-01, Vol.14 (1), p.118

2022

Volltextzugriff (PDF)

Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors

Cell reports (Cambridge), 2022-05, Vol.39 (8), p.110839-110839, Article 110839

2022

Volltextzugriff (PDF)

Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas

Clinical cancer research, 2017-10, Vol.23 (20), p.6215-6226

2017

Volltextzugriff (PDF)

NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors

Nature medicine, 2012-12, Vol.18 (12), p.1827

2012

Volltextzugriff (PDF)

Oncolytic HSV-Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition

Clinical cancer research, 2020-05, Vol.26 (10), p.2381-2392

2020

Volltextzugriff (PDF)

BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy

Clinical cancer research, 2017-04, Vol.23 (7), p.1809-1819

2017

Volltextzugriff (PDF)

1 – 25 von 262

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(247)
Mit Volltextzugriff
(246)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma

Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas

The Notch signaling pathway: a potential target for cancer immunotherapy

Rat and Mouse Brain Tumor Models for Experimental Neuro-Oncology Research

Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis

Impact of tumor microenvironment on oncolytic viral therapy

Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth

MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

Selective Endothelial Hyperactivation of Oncogenic KRAS Induces Brain Arteriovenous Malformations in Mice

Complex role of NK cells in regulation of oncolytic virus–bortezomib therapy

Histone modifiers at the crossroads of oncolytic and oncogenic viruses

A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases

RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21

Pyruvate kinase M2 regulates homologous recombination-mediated DNA double-strand break repair

Glioma and temozolomide induced alterations in gut microbiome

PRMT5 as a druggable target for glioblastoma therapy

Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells

NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy

Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors

Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors

Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas

NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors

Oncolytic HSV-Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition

BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy

Suchergebnisse filtern